BioSpace News Archive

Gilead announced its plans to replant some roots back in North Carolina’s Research Triangle. The new site is expected to bring in 275 jobs to the North Hills innovation district.

With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

In a late-breaking presentation on Saturday, EQRx and partner CStone Pharmaceuticals will report data from the phase III GEMSTONE-301 study of its anti-PD-L1 antibody sugemalimab.

The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.

Vifor Pharma Group and Travere Therapeutics inked a collaborationfor the commercialization of sparsentan for the treatment rare progressive kidney diseases.

From time to time, the U.S. FDA requests additional data from companies who have submitted an application for a new drug or biologic. What’s a bit unusual is every single PDUFA date this week had that happen.

A trustee with the DOJ filed a request for an “expedited stay” in order to prevent the initiation of the bankruptcy plan.

COVID-19 remains relentless in challenging the community as it continues to evolve. Here are some of the top news for the week.

VBL Therapeutics announced that the independent Data Safety Monitoring Committee of the ongoing OVAL Phase 3 registration-enabling study of VB-111 in ovarian cancer has conducted its fifth pre-planned review and has provided clearance to proceed with further clinical research as planned with no changes to the protocol.

Enveric Biosciences announced the closing of its acquisition of MagicMed Industries Inc., a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine and other molecular derivatives with applications across multiple indications, in an all-stock transaction.